Transitions in treatment: A systematic review and meta-aggregation of preferences and barriers in switching from oral to long-acting injectable antiretroviral therapy among people living with HIV and stakeholders
- PMID: 39748161
- DOI: 10.1111/hiv.13756
Transitions in treatment: A systematic review and meta-aggregation of preferences and barriers in switching from oral to long-acting injectable antiretroviral therapy among people living with HIV and stakeholders
Abstract
Introduction: Antiretroviral treatment (ART) has significantly enhanced health outcomes for people living with HIV (PLWH). With the evolution of treatment options, there is an increasing interest in the development of long-acting injectable formulations of antiretroviral drugs. These formulations present a promising alternative to oral ART.
Methods: The methodology and reporting of this systematic review followed the guidance of the Joanna Briggs Institute Reviewer's Manual and Enhancing Transparency in Reporting the Synthesis of Qualitative Research (ENTREQ). The comprehensive searches involved multiple databases, including PubMed, MEDLINE (Ovid), Embase (Ovid), CINHAL (EBSCO), ProQuest Dissertations and Theses, Web of Science, Wanfang (Chinese), CNKI (Chinese), Google Scholar and Baidu Scholar (Chinese).
Results: In all, 142 studies were identified and 20 eligible studies were included in the meta-aggregation. A total of 141 findings, 20 categories and nine synthesized findings were extracted from 20 studies. The nine synthesized findings identified from the 20 studies focused on the following topics: benefits, flexibility and practicality of long-acting injectable (LAI) treatment; scepticism about the use of LAI treatment; management challenges; logistical challenges; potential for protecting marginalized populations; concerns about side effects; financial issue; suggestions for improvement. PLWH's geographical distribution, backgrounds, demographics and clinical characteristics were limited.
Conclusion: We recommend considering the needs and experiences of PLWH in the transition from oral ART to LAI treatment. For marginalized populations, it is crucial to maintain regular communication with healthcare providers and institutions. Additionally, at the community level, engaging diverse stakeholders with valuable insights is vital, as is enhancing health education programmes and intensifying efforts to combat discrimination. These measures will play a key role in addressing the needs of PLWH, enhancing public awareness and promoting better understanding of LAI treatment.
Keywords: HIV; antiretroviral treatment (ART); long‐acting injectable (LAI) treatment; meta‐aggregation; people living with HIV (PLWH); systematic review.
© 2025 British HIV Association.
Similar articles
-
Bridging the gap: identifying barriers and strategies for widespread implementation of long-acting injectable antiretroviral therapy in Sub-Saharan Africa: a scoping review.BMC Infect Dis. 2025 Apr 8;25(1):476. doi: 10.1186/s12879-025-10871-0. BMC Infect Dis. 2025. PMID: 40200165 Free PMC article.
-
Long-acting injectable ART to advance health equity: a descriptive analysis of US clinic perspectives on barriers, needed support and programme goals for implementation from applications to the ALAI UP Project.J Int AIDS Soc. 2024 Jul;27 Suppl 1(Suppl 1):e26282. doi: 10.1002/jia2.26282. J Int AIDS Soc. 2024. PMID: 38965977 Free PMC article.
-
Perceptions of Long-Acting Injectable Antiretroviral Therapy Among People Living with HIV Who Use Drugs and Service Providers: a Qualitative Analysis in Rhode Island.J Urban Health. 2023 Oct;100(5):1062-1073. doi: 10.1007/s11524-023-00755-6. Epub 2023 Aug 10. J Urban Health. 2023. PMID: 37563518 Free PMC article.
-
Long-Acting Injectable ART in Practice: A Mixed Methods Implementation Study Assessing the Feasibility of Using LAI ART in High Risk Populations and At Alternative Low Barrier Care Sites.AIDS Patient Care STDS. 2024 May;38(5):221-229. doi: 10.1089/apc.2024.0048. Epub 2024 Apr 24. AIDS Patient Care STDS. 2024. PMID: 38656905 Free PMC article.
-
Long-Acting Injectable Antiretroviral Therapy for Treatment of Human Immunodeficiency Virus: A Review.Curr HIV/AIDS Rep. 2025 Apr 23;22(1):31. doi: 10.1007/s11904-025-00741-4. Curr HIV/AIDS Rep. 2025. PMID: 40266468 Review.
Cited by
-
Willingness to Take Long-Acting Injectable Preexposure Prophylaxis (PrEP) and Preference for PrEP Modalities Among People Who Inject Drugs in Washington, DC.Open Forum Infect Dis. 2025 Jul 3;12(7):ofaf389. doi: 10.1093/ofid/ofaf389. eCollection 2025 Jul. Open Forum Infect Dis. 2025. PMID: 40672761 Free PMC article.
References
REFERENCES
-
- Eisinger RW, Dieffenbach CW, Fauci AS. HIV viral load and transmissibility of HIV infection: undetectable equals untransmittable. JAMA. 2019;321(5):451‐452.
-
- Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the international Antiviral society–USA panel. JAMA. 2018;320(4):379‐396.
-
- Kanters S, Vitoria M, Doherty M, et al. Comparative efficacy and safety of first‐line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta‐analysis. Lancet HIV. 2016;3(11):e510‐e520.
-
- Nachega JB, Scarsi KK, Gandhi M, et al. Long‐acting antiretrovirals and HIV treatment adherence. Lancet HIV. 2023;10:e332‐e342.
-
- Schatz E, Knight L, Mukumbang FC, Teti M, Myroniuk TW. ‘You have to withstand that because you have come for what you have come for’: barriers and facilitators to antiretroviral treatment access among older south Africans living with HIV. Sociol Health Illn. 2021;43(3):624‐641.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical